Navigation Links
CRESTOR Cuts Risk of Stroke by Nearly Half in JUPITER Study
Date:2/19/2009

p>CRESTOR is indicated as an adjunct to diet to reduce elevated Total-C, LDL-C, ApoB, non-HDL-C, and TG levels and to increase HDL-C in patients with primary hyperlipidemia and mixed dyslipidemia. CRESTOR is also indicated as an adjunct to diet to slow the progression of atherosclerosis in adult patients as part of a treatment strategy to lower Total-C and LDL-C to target levels. CRESTOR is not approved to prevent cardiovascular morbidity and mortality.

CRESTOR is contraindicated in patients with a known hypersensitivity to any component of this product, in patients with active liver disease, which may include unexplained persistent elevations of hepatic transaminase levels, in women who are pregnant or may become pregnant, and in nursing mothers.

Cases of myopathy and rhabdomyolysis with acute renal failure secondary to myoglobinuria have been reported with HMG-CoA reductase inhibitors, including CRESTOR. These risks can occur at any dose level, but are increased at the highest dose (40 mg).

CRESTOR should be prescribed with caution in patients with predisposing factors for myopathy (eg, age greater than or equal to 65 years, inadequately treated hypothyroidism, renal impairment). The risk of myopathy during treatment with CRESTOR may be increased with concurrent administration of some other lipid-lowering therapies (fibrates or niacin), gemfibrozil, cyclosporine, or lopinavir/ritonavir.

Therapy with CRESTOR should be discontinued if markedly elevated CK levels occur or myopathy is diagnosed or suspected. All patients should be advised to promptly report unexplained muscle pain, tenderness, or weakness, particularly if accompanied by malaise or fever. It is recommended that liver enzyme tests be performed before and at 12 weeks following both the initiation of therapy and any elevation of dose, and periodically (e.g., semiannually) thereafter. Should an increase in ALT or AST of >3 times ULN p
'/>"/>

SOURCE AstraZeneca
Copyright©2009 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4

Related medicine news :

1. Analyst Available to Comment on New JUPITER Study That Shows AstraZenecas Crestor Significantly Reduces CV Risk
2. CRESTOR(R) Now Indicated to Slow the Progression of Atherosclerosis in Patients With Elevated Cholesterol
3. B Vitamins Might Lower Stroke Risk
4. Women less likely to receive critical care after a stroke, MSU researchers find
5. Study shows ultrasound and tPA effective for stroke
6. Working With Robots May Help After a Stroke
7. Silent Strokes More Common in Younger People Than Thought
8. ER Less Likely to Diagnose Stroke in Younger Folks
9. Fast Arrival at Hospital After Stroke Pays Off
10. Coffee Drinking Lowers Womens Stroke Risk
11. Gender Disparities Persist in Treatment of Stroke
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2009)... have really been in trouble, expert says , , TUESDAY, ... pandemic H1N1 swine flu has revealed serious flaws in ... a new report says. , The report, prepared by ... Johnson Foundation, also finds the dire economy has strained ... H1N1 outbreak is the latest in a series of ...
(Date:12/15/2009)... delivered ,, WASHINGTON, Dec. 15 ... that healthcare reform does not override the prostate ... in 37 states. ,, Prostate cancer screening is ... and individuals who are identifiable as high risk, ... a family history of prostate cancer. The American ...
(Date:12/15/2009)... BERWYN, Pa., Dec. 15 4R Systems, ... supply chain solutions which help retailers significantly increase ... chain decisions, announced today that The Vitamin Shoppe ... 2008. ,, "4R,s store and DC inventory solutions ... inventory efficiency and in-stocks over the last two ...
(Date:12/15/2009)... NEW YORK, Dec. 15 The following are ... Attorney General for the criminal division, at the ... you, Secretary Sebelius. And thank you for the ... the HEAT initiative. ,, Together, our Departments ... lasting results. ,, We,ve made tremendous progress in ...
(Date:12/15/2009)... Continuing Strike Force Operations Lead to Indictment of ... with more than $61 Million in Fraudulent Billing ... Thirty people have been charged in ... to submit more than $61 million in false ... of the Medicare Fraud Strike Force, Department of ...
Breaking Medicine News(10 mins):Health News:Serious Gaps Revealed in U.S. Response to Health Emergencies 2Health News:Serious Gaps Revealed in U.S. Response to Health Emergencies 3Health News:Men's Health Network Calls on Congress to Complete President Obama's Promise on Health Care Reform 2Health News:4R's Profit Optimizing Inventory Solutions Helps The Vitamin Shoppe Drive Increased Productivity and Performance 2Health News:4R's Profit Optimizing Inventory Solutions Helps The Vitamin Shoppe Drive Increased Productivity and Performance 3Health News:4R's Profit Optimizing Inventory Solutions Helps The Vitamin Shoppe Drive Increased Productivity and Performance 4Health News:Remarks by Lanny A. Breuer, Assistant Attorney General for the Criminal Division, at the Medicare Fraud Strike Force Press Conference 2Health News:Remarks by Lanny A. Breuer, Assistant Attorney General for the Criminal Division, at the Medicare Fraud Strike Force Press Conference 3Health News:Medicare Fraud Strike Force Expands Operations Into Brooklyn, N.Y.; Tampa, Fla.; and Baton Rouge, La. 2Health News:Medicare Fraud Strike Force Expands Operations Into Brooklyn, N.Y.; Tampa, Fla.; and Baton Rouge, La. 3Health News:Medicare Fraud Strike Force Expands Operations Into Brooklyn, N.Y.; Tampa, Fla.; and Baton Rouge, La. 4Health News:Medicare Fraud Strike Force Expands Operations Into Brooklyn, N.Y.; Tampa, Fla.; and Baton Rouge, La. 5
... follows ConAgra Foods Advisory on Pot Pies containing ... Stop & Shop,Supermarket Company LLC, following a product ... its shelves all ConAgra 7 oz. Banquet Pot,Pies ... the alert today., As a precautionary measure, ...
... Guttmacher,Institute,s latest report on world abortion rates is ... W. Mosher. The,study, just released today, argues that ... developing countries., Accurate numbers are impossible to ... illegal. Says Mosher: "Neither,Guttmacher nor anyone else knows ...
... they can potentially target chemotherapy for breast cancer to ... majority of patients from unnecessary side effects. , ... Cancer Center researchers, found women whose breast cancer expressed ... from adding the drug Taxol to the chemotherapy regimen, ...
... Oct. 10 Good Shepherd,Rehabilitation Network has ... Rehability. The virtual store at, http://www.rehabilitystores.com ... capability of secure online shopping specifically for ... aging, and their caregivers., "Rehability offers ...
... XYIENCE(R) Inc. (pronounced,zy-ince), one of the fastest growing ... that the company has received access,to up to $12 ... of,investors. The company intends to use a significant portion ... energy drink. The,name Xenergy is a combination of Zen ...
... leadership team; restructures business units ... ... announced the appointments of Paul D. Colvin as senior vice,president of ... of clinical operations for Asia. Mr. Colvin joins PPD from ...
Other Medicine News:Health News:Stop & Shop Alerts Customers to Product Advisory by ConAgra Foods 2Health News:PRI Criticizes Guttmacher Report 2Health News:HER-2 status predicts success of chemotherapy in breast cancer treatment, study finds 2Health News:HER-2 status predicts success of chemotherapy in breast cancer treatment, study finds 3Health News:Those With Disabilities as Well as Aging Population Throughout Country Now Have Access to Thousands of Specialized Products 2Health News:XYIENCE(R) Announces $12 Million Funding and Signing of Long Term UFC(R) Sponsorship 2Health News:PPD Names VPs for North America and Asia 2Health News:PPD Names VPs for North America and Asia 3
(Date:12/15/2009)... opportune time to find the best plan at the ... Through the end of the year, thousands ... about their health coverage. This is when the ... benefits they will sign up and pay for in ... part of this decision, says Independent Retail Pharmacist Steve ...
(Date:12/15/2009)... Fenwal Inc., a global medical technology ... and availability, announced today that the U.S. Food ... market InterSol ® platelet additive solution. ... a specialized product used in combination with human ... component used to prevent or treat bleeding. ,, ...
(Date:12/15/2009)... ,, Reportlinker.com announces that a new market ... ,, Hepatitis B Vaccines - Pipeline ... ,, http://www.reportlinker.com/p0167309/Hepatitis-B-Vaccines---Pipeline-Analysis-and-Market-Forecasts-to-2015.html ,, Hepatitis B ... to 2015 ,, Summary ,, ... "Hepatitis B Vaccines - Pipeline Analysis and ...
Breaking Medicine Technology:Pharmacist Urges Nebraska Medicare Beneficiaries to Compare Prescription Plans 2Fenwal Receives FDA Approval for New Solution Used to Store Donated Blood Platelets 2Reportlinker Adds Hepatitis B Vaccines - Pipeline Analysis and Market Forecasts to 2015 2Reportlinker Adds Hepatitis B Vaccines - Pipeline Analysis and Market Forecasts to 2015 3Reportlinker Adds Hepatitis B Vaccines - Pipeline Analysis and Market Forecasts to 2015 4Reportlinker Adds Hepatitis B Vaccines - Pipeline Analysis and Market Forecasts to 2015 5Reportlinker Adds Hepatitis B Vaccines - Pipeline Analysis and Market Forecasts to 2015 6Reportlinker Adds Hepatitis B Vaccines - Pipeline Analysis and Market Forecasts to 2015 7Oxygen Biotherapeutics Inc Posts Blog by CEO Chris Stern on Proposed Reverse Split 57452 1Bayer Announces New Data on Oncology Portfolio To Be Presented at the ECCO ESMO Congress 2009 5015 1Bayer Announces New Data on Oncology Portfolio To Be Presented at the ECCO ESMO Congress 2009 5015 2Bayer Announces New Data on Oncology Portfolio To Be Presented at the ECCO ESMO Congress 2009 5015 3Bayer Announces New Data on Oncology Portfolio To Be Presented at the ECCO ESMO Congress 2009 5015 4Bayer Announces New Data on Oncology Portfolio To Be Presented at the ECCO ESMO Congress 2009 5015 5Bayer Announces New Data on Oncology Portfolio To Be Presented at the ECCO ESMO Congress 2009 5015 6Veteran Intellectual Property Team Joins Brown Rudnick 14113 1Veteran Intellectual Property Team Joins Brown Rudnick 14113 2
... Demonstrated Strong Reduction of Pain,Intensity, SYDNEY, ... QRxPharma Limited (ASX: QRX), a,clinical-stage specialty ... of therapies for pain and central nervous ... efficacy results for,Q8003IR, an immediate release dual-opioid ...
... BOULDER, Colo., May 5 N30 Pharma (N30), ... of drugs that target endogenous s-nitrosothiols,announced today that ... N30-201,in patients with mild to moderate asthma, as ... for the treatment of reactive and,obstructive airway diseases, ...
Other Medicine Technology:QRxPharma Releases Successful Phase 3 Study Results for 'Dual Opioid' Pain Therapy 2QRxPharma Releases Successful Phase 3 Study Results for 'Dual Opioid' Pain Therapy 3N30 Pharma Announces Completion of Phase 1 Clinical Studies With N30-201 2
Tube for Left Bronchus - Ruschelit™ PVC. Color coded for easy identification of ports, balloons and 15mm connectors. High volume/low pressure cuffs. With Carina hook. X-ray opaque line. Graduat...
... Topical Anesthetic, ,Designed for adolescent ... incorporates an additional lumen and injection ... anesthetic above and below the cuff., ... designs which allow for CO2 monitoring, ...
Laryngectomy Tubes with special J-shape for convenient placement through a tracheostomy stoma....
SHERIDAN PREFORMED Endotracheal Tubes are designed to conveniently position the anesthesia circuit out of the surgical field for oral and maxillofacial procedures....
Medicine Products: